Chimeric Therapeutics Limited
OTC: CHMMF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Rebecca McQualter
- Headquarters
- Carlton, Australia
- IPO year
- 2022
- Market cap
- $4.1M
- Website
- https://www.chimerictherapeutics.com
Loading CHMMF…
Loading profile data…Frequently asked questions about CHMMF
What does Chimeric Therapeutics Limited (CHMMF) do?
Chimeric Therapeutics Limited is an Australian biotechnology firm operating at the clinical stage, dedicated to advancing and commercializing a diverse portfolio of cell-based treatments specifically for cancer. Its pipeline features several promising candidates. CHM 0201, utilizing a core natural killer (NK) cell platform, is currently undergoi...
Where does CHMMF trade?
Chimeric Therapeutics Limited (CHMMF) trades on the Other OTC.
What sector is CHMMF in?
Chimeric Therapeutics Limited (CHMMF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Chimeric Therapeutics Limited?
Rebecca McQualter is the chief executive officer of Chimeric Therapeutics Limited (CHMMF).
Where is Chimeric Therapeutics Limited headquartered?
Chimeric Therapeutics Limited is headquartered in Australia.
Does CHMMF pay a dividend?
Chimeric Therapeutics Limited (CHMMF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CHMMF go public?
Chimeric Therapeutics Limited (CHMMF) completed its initial public offering in 2022.